Coloplast A/S said its pretax profit for the fiscal third quarter rose 12.5% year over year and confirmed its revenue outlook for the fiscal year.
Pretax profit totaled 1.39 billion Danish kroner, up from 1.23 billion kroner in the year-earlier period. EPS came in at 5.02 kroner, a gain of 12.3% from 4.47 kroner in the prior-year period.
Coloplast's after-tax net profit climbed 12.7% on a yearly basis to 1.07 billion kroner from 948.0 million kroner.
The Danish company, whose products include wound dressings and body waste collection devices, said its revenue grew 9% year over year to 4.60 billion kroner from 4.23 billion kroner.
For the nine months ended June 30, pretax profit reached 4 billion kroner, a 9.7% year-over-year increase from 3.65 billion kroner. After-tax net profit rose to 3.08 billion kroner from 2.81 billion a year earlier.
Revenue for the nine-month period amounted to 13.32 billion kroner, up 9.1% on an annual basis from 12.22 billion kroner.
For the full fiscal year, Coloplast still estimates organic revenue growth in Danish kroner of about 9%.
In other news, the Denmark-based healthcare supplies company expects to complete the unconditional strategic review of its interventional urology unit by the end of 2019.
As of Aug. 13, US$1 was equivalent to 6.67 Danish kroner.